Program Goals

This program is designed to improve clinical awareness of the fragile X syndrome (FXS) and in particular the role the causative gene FMR1 plays in premature ovarian failure. Historical and updated findings concerning the syndrome and FMR1 will be presented, along with requirements for accurate laboratory tests. Special emphasis is placed on the relationship between fragile X status (number of CGG repeats) and premature ovarian failure (POF), and strategy for prenatal genetic diagnosis.

Target Audience

Obstetricians/Gynecologists, Ph.D. Clinical Geneticists, M.D. Medical Geneticists, Genetic Counselors, Pediatricians, Nurses, Mental Health Specialists, Laboratory Professionals, and related healthcare professionals interested or involved in the clinical management of fragile X syndrome (FXS).

Educational Objectives

After completing this activity, the participant should be able to:

1. Explain why disturbances of the FMR1 gene less frequently cause mental retardation in females than males.
2. Define premutation with respect to Fragile X syndrome and its (FMR1) gene.
3. Describe how a carrier (premutation) having 55-199 CGG repeats can have offspring with mental retardation.
4. State the likelihood of a sporadic or familial case of POF showing a premutation.
5. Discuss the relationship of POF to number of CGG repeats.

Faculty

Joe Leigh Simpson, MD
Executive Associate Dean for Academic Affairs / Professor of Obstetrics and Gynecology
Professor of Human and Molecular Genetics
Florida International University College of Medicine
11200 Southwest 8th Street, HLS 693, Miami, Florida 33199

Kenneth J. Friedman, PhD
Director of Molecular Genetics
Center for Molecular Biology and Pathology
Laboratory Corporation of America
1912 Alexander Drive, Research Triangle Park, NC 27709

Agenda

05 minutes: Welcome & Introduction
65 minutes: Faculty Presentations
15 minutes Q&A Session
05 minutes: Evaluation & Post-Test

Disclosure of Conflicts of Interests

Instructors, planners, managers and other individuals who are in a position to control the content of this activity are required to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Faculty Disclosures

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this P.A.C.E.^®accredited activity:

Planners and Managers

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Credit Designation - Lab Professional, P.A.C.E.^®

The American Society for Clinical Laboratory Science's Professional Acknowledgment for Continuing Education (P.A.C.E.^®) Program will provide 1.5 contact hour of credit.

How to Obtain P.A.C.E.^® Credit

ACCREDITATION FOR THIS ACTIVITY HAS EXPIRED

Viewers are expected to complete the presentation before attempting to submit contact information and the session evaluation. Successful completion will lead to the issuance of a certificate for 1.5 contact hour of P.A.C.E.^® approved continuing education. To receive credit, the course must be completed by October 1, 2012.

Participation in this activity should be completed in approximately 1.5 hours. Please follow these steps in order to receive P.A.C.E.^® credit for viewing the webcast:

• Read all of the information above.
• View the complete webcast program.
• Click on the link to apply for P.A.C.E.^® credit.
• Complete the online registration (registration is free).
• Complete the online test and/or evaluation. Participants must receive a test score of at least 70% and answer all evaluation questions to receive a certificate.
• After successful completion of this process, you will be redirected to the ASCLS CE Organizer where you may create and print an official ASCLS P.A.C.E.^® certificate based on your attendance and completion of this ASCLS-sponsored P.A.C.E.^® approved learning activity.

Should you have any P.A.C.E.^® questions regarding this activity, please contact:

ASCLS P.A.C.E.^®
1861 International Drive, Suite 200
Tysons Corner, VA 22102
Ph: 571-748-3776
Fx: 571-354-7576
http://www.ascls.org/

Release and Expiration

Release Date: October 1, 2011
Expiration date: October 1, 2012

Fee Information

There is no fee for this educational activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The American Society for Clinical Laboratory Science (ASCLS) and Dane Garvin Ltd. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Policy on Privacy and Confidentiality

Dane Garvin Ltd. protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. Dane Garvin Ltd. will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

Dane Garvin, Ltd. maintain physical, electronic and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Medium Used

This program has been made available online.

"Fragile X Syndrome: Premature Ovarian Failure and Molecular Diagnosis"

System Requirements

To view this educational activity you will need a web browser with Javascript and either Flash or HTML5 enabled.  Nearly all modern web browsers will work.

Cosponsors

Cosponsored by:

Commercial Support Statement

    This activity supported by an educational grant from Abbott Molecular.

Copyright

Copyright © October 1, 2011 - October 1, 2012   Dane Garvin, Ltd.   All Rights Reserved.   Permission for accreditation use granted to the American Society for Clinical Laboratory Science (ASCLS).